研究文章

非肌层浸润性膀胱癌患者术后复发预测模型的研究

摘要

目的:识别非肌层浸润性膀胱癌(NMIBC)术后复发的影响因素,构建列线图预测模型。方法:回顾性分析NMIBC患者282例,按7:3随机分层分为训练集和验证集。通过单因素、多因素logistic分析复发的影响因素,构建验证预测模型。结果:肿瘤多发、肿瘤直径、病理分级、高SII为危险因素,维持膀胱灌注治疗是保护因素(P<0.05)。ROC曲线、校准曲线及决策曲线证实了该模型的临床实用性。结论该预测模型可较准确评估NMIBC术后复发风险,有助于临床术后管理。

关键词

非肌层浸润性膀胱癌;经尿道膀胱肿瘤切除术;术后复发;预测模型

参考

陆玲玲,孙燕,严永锋,等.全球及中国膀胱癌流行特征分析与趋势预测——基于GLOBOCAN 2022数据库[J].中国肿瘤,2025,34(7):499-506.

van Zutphen M,Beeren I,Aben K K H,et al.Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer[J].Cancer medicine,2023,12(20):20459-20469.

Teoh J Y C,Kamat A M,Black P C,et al.Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective[J].Nature reviews Urology,2022,19(5):280-294.

凌能勇,汪盛.全身炎症反应指数评估高级别非肌层浸润性膀胱癌患者预后的价值[J]. 中华全科医学,2024,22(7):1138-1141.

邵鑫丽,赵一涵,吴艳萍.个体化预测非肌层浸润性膀胱癌患者经尿道膀胱肿瘤电切术后复发风险的列线图模型建立[J].微创泌尿外科杂志,2025,14(6):380-384.

曹敬毅,王乾,王淇超,等.非肌层浸润性膀胱尿路上皮癌320例的复发及进展[J].现代泌尿外科杂志,2022,27(1):26-29.

Peng R,Zhang Y,Jia M,et al.Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67[J].Frontiers in Oncology,2025,14:1522009.

Nebioglu A,Basaranoglu M,Bozlu M,et al.Impact of lymphovascular invasion and histological variants on BCG-treated high-grade NMIBC prognosis[J].Bladder cancer,2025,11(3):23523735251370645.

Bai J,Huang Y,Chen B,et al.Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis[J].Frontiers in oncology,2025,15:1707657.

潘盼,郭灿琮,朱要辉,等.全身免疫炎症指数联合血小板与淋巴细胞比值、残余尿量对高危非肌层浸润性膀胱癌术后复发的预测价值[J].中国实用医刊,2026,53(14):1004-1008.

叶德宇,杨帅,赵龙龙,等.炎性标志物对恶性肿瘤发生发展和预后的影响及其机制的研究进展[J].吉林大学学报(医学版),2022,48(4):1079-1087.

Deng-Xiong L,Qing-Xin Y,De-Chao F,et al.Systemic Immune-inflammation Index (SII) During Induction has Higher Predictive Value Than Preoperative SII in Non-muscle-invasive Bladder Cancer Patients Receiving Intravesical Bacillus Calmette -Guerin[J].Clinical genitourinary cancer,2023,21(3): e145-e152.

Qian J,Zhang Q,Cao Y,et al.Perfusion drugs for non‑muscle invasive bladder cancer (Review)[J].Oncology letters,2024,27(6):267.

Holzbeierlein J M,Bixler B R,Buckley D I,et al.Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment[J].The Journal of urology,2024,211(4):533-538.84

Refbacks

  • 当前没有refback。
版权所有(c)2026 豪 徐, 强 迟
Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。